Home › Companies › AngioDynamics, Inc. › 2024-2025

AngioDynamics, Inc. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and AngioDynamics, Inc.’s Form 8-K, filed November 15, 2024 (Item 5.07 on EDGAR). Page generated October 18, 2026.

  • 6Ballot items
  • 157Asset managers
  • 1,148Fund votes
  • November 12, 2024Meeting date

Results at a glance

Meeting of November 12, 2024: 6 items on AngioDynamics, Inc.’s Form 8-K, filed November 15, 2024: 3 elected · 3 approved.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore AngioDynamics, Inc. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by AngioDynamics, Inc.

These tallies are AngioDynamics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed November 15, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

AngioDynamics, Inc. — official shareholder meeting results, meeting held November 12, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Lorinda A. Burgess 26,292,870---- 1,996,0955,993,164 93%Elected—
Elect Director: Wesley E. Johnson, Jr. 24,817,356---- 3,471,6095,993,164 88%Elected—
Elect Director: Karen A. Licitra 26,276,748---- 2,012,2175,993,164 93%Elected—
2. The proposal to ratify the appointment of Deloitte & Touche LLP as AngioDynamics' independent registered public accounting firm for the fiscal year ending May 31, 2025 34,110,530155,07716,522 ---- 99.5%Approved—
3. The proposal to approve, on an advisory basis, AngioDynamics' executive compensation of its named executive officers 26,004,9081,248,4791,035,578 --5,993,164 95%Approved—
4. The proposal to approve the amended AngioDynamics, Inc. 2020 Equity Incentive Plan 23,195,3465,058,46835,151 --5,993,164 82%Approved—

Source: AngioDynamics, Inc., Form 8-K, filed with the SEC on November 15, 2024 — read the filing on EDGAR.

How asset managers voted at the AngioDynamics, Inc. 2024-2025 meeting

Each item below shows how the 157 asset managers that disclosed a AngioDynamics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Karen A. Licitra

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%
FOR: 26,276,748WITHHELD: 2,012,217
Details: description as filed, official tally, votes by 53 asset managers

Description as filed by funds: Proposal to elect three Class III directors, for a term of three years: Karen A. Licitra

AngioDynamics, Inc.’s own tally for this item (“Elect Director: Karen A. Licitra”): 26,276,748 for, 2,012,217 withheld, per its Form 8-K filed November 15, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The nominees for election to the Board of Directors were elected, each as a Class III director to serve until the 2027 Annual Meeting of Shareholders and until their respective successors are duly elected and qualified, based upon the following votes:”
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 53 asset managers below reported 10,417,859 for, 143 withheld.

FOR
FOR: 10,417,859WITHHOLD: 143
Largest asset managers voting on “Proposal to elect three Class III directors, for a term of three years: Karen A. Licitra” at AngioDynamics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard2,252,3660 00For
BlackRock1,914,0790 00For
Dimensional1,086,1220 00For
Fidelity984,9370 00For
TIAA941,1410 00For
Royce569,4100 00For
FIRST EAGLE FUNDS348,8960 00For
Charles Schwab330,1300 00For
Transamerica319,9000 00For
Columbia Threadneedle216,9510 00For
Segall Bryant & Hamill Trust205,6200 00For
Nationwide150,9360 00For
Equitable135,0650 00For
JPMorgan129,4670 00For
Invesco100,8280 00For
BRIDGEWAY FUNDS INC83,5000 00For
QUANTITATIVE MASTER SERIES LLC71,6540 00For
Lincoln Financial62,9190 00For
MASTER INVESTMENT PORTFOLIO54,0790 00For
American Century52,8790 00For
Voya42,2670 00For
GuideStone40,6060 00For
Putnam31,9870 00For
ADVISORS' INNER CIRCLE FUND27,7790 00For
Goldman Sachs27,1080 00For

Showing the 25 largest of 53 asset managers. See all 53 in the interactive database.

2. Elect Director: Lorinda A. Burgess

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%
FOR: 26,292,870WITHHELD: 1,996,095
Details: description as filed, official tally, votes by 53 asset managers

Description as filed by funds: Proposal to elect three Class III directors, for a term of three years: Lorinda A. Burgess

AngioDynamics, Inc.’s own tally for this item (“Elect Director: Lorinda A. Burgess”): 26,292,870 for, 1,996,095 withheld, per its Form 8-K filed November 15, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The nominees for election to the Board of Directors were elected, each as a Class III director to serve until the 2027 Annual Meeting of Shareholders and until their respective successors are duly elected and qualified, based upon the following votes:”
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 53 asset managers below reported 10,417,859 for, 143 withheld.

FOR
FOR: 10,417,859WITHHOLD: 143
Largest asset managers voting on “Proposal to elect three Class III directors, for a term of three years: Lorinda A. Burgess” at AngioDynamics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard2,252,3660 00For
BlackRock1,914,0790 00For
Dimensional1,086,1220 00For
Fidelity984,9370 00For
TIAA941,1410 00For
Royce569,4100 00For
FIRST EAGLE FUNDS348,8960 00For
Charles Schwab330,1300 00For
Transamerica319,9000 00For
Columbia Threadneedle216,9510 00For
Segall Bryant & Hamill Trust205,6200 00For
Nationwide150,9360 00For
Equitable135,0650 00For
JPMorgan129,4670 00For
Invesco100,8280 00For
BRIDGEWAY FUNDS INC83,5000 00For
QUANTITATIVE MASTER SERIES LLC71,6540 00For
Lincoln Financial62,9190 00For
MASTER INVESTMENT PORTFOLIO54,0790 00For
American Century52,8790 00For
Voya42,2670 00For
GuideStone40,6060 00For
Putnam31,9870 00For
ADVISORS' INNER CIRCLE FUND27,7790 00For
Goldman Sachs27,1080 00For

Showing the 25 largest of 53 asset managers. See all 53 in the interactive database.

3. Elect Director: Wesley E. Johnson, Jr.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%
FOR: 24,817,356WITHHELD: 3,471,609
Details: description as filed, official tally, votes by 53 asset managers

Description as filed by funds: Proposal to elect three Class III directors, for a term of three years: Wesley E. Johnson, Jr.

AngioDynamics, Inc.’s own tally for this item (“Elect Director: Wesley E. Johnson, Jr.”): 24,817,356 for, 3,471,609 withheld, per its Form 8-K filed November 15, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The nominees for election to the Board of Directors were elected, each as a Class III director to serve until the 2027 Annual Meeting of Shareholders and until their respective successors are duly elected and qualified, based upon the following votes:”
Support: 88% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 53 asset managers below reported 10,202,915 for, 215,087 withheld.

FOR
FOR: 10,202,915WITHHOLD: 215,087
Largest asset managers voting on “Proposal to elect three Class III directors, for a term of three years: Wesley E. Johnson, Jr.” at AngioDynamics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard2,252,3660 00For
BlackRock1,914,0790 00For
Dimensional1,086,1220 00For
Fidelity984,9370 00For
TIAA941,1410 00For
Royce569,4100 00For
FIRST EAGLE FUNDS348,8960 00For
Charles Schwab330,1300 00For
Transamerica319,9000 00For
Columbia Threadneedle216,9510 00For
Segall Bryant & Hamill Trust205,6200 00For
Nationwide150,9360 00For
Equitable135,0650 00For
JPMorgan129,4670 00For
Invesco00 0100,828Withhold
BRIDGEWAY FUNDS INC00 083,500Withhold
QUANTITATIVE MASTER SERIES LLC71,6540 00For
Lincoln Financial62,9190 00For
MASTER INVESTMENT PORTFOLIO54,0790 00For
American Century52,8790 00For
Voya42,2670 00For
GuideStone40,6060 00For
Putnam31,9870 00For
ADVISORS' INNER CIRCLE FUND00 027,779Withhold
Goldman Sachs27,1080 00For

Showing the 25 largest of 53 asset managers. See all 53 in the interactive database.

4. 4. The proposal to approve the amended AngioDynamics, Inc. 2020 Equity Incentive Plan

Official resultCOMPENSATIONReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

82% Approved · of votes cast

FOR 82%AGAINST
FOR: 23,195,346AGAINST: 5,058,468
Details: description as filed, official tally, votes by 55 asset managers

Description as filed by funds: Approval of an amendment to increase the number of shares available for issuance under the AngioDynamics, Inc. 2020 Equity Incentive Plan.

AngioDynamics, Inc.’s own tally for this item (“4. The proposal to approve the amended AngioDynamics, Inc. 2020 Equity Incentive Plan”): 23,195,346 for, 5,058,468 against — passed, per its Form 8-K filed November 15, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The proposal to approve the amended AngioDynamics, Inc. 2020 Equity Incentive Plan was approved based upon the following votes:”
Support: 82% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 55 asset managers below reported 9,117,545 for, 1,355,978 against.

FOR
FOR: 9,117,545AGAINST: 1,355,978
Largest asset managers voting on “Approval of an amendment to increase the number of shares available for issuance under the AngioDynamics, Inc.” at AngioDynamics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard2,252,3660 00For
BlackRock1,914,0790 00For
Dimensional1,086,1220 00For
Fidelity984,9370 00For
TIAA0941,141 00Against
Royce569,4100 00For
FIRST EAGLE FUNDS348,8960 00For
Charles Schwab330,1300 00For
Transamerica319,9000 00For
Columbia Threadneedle0216,951 00Against
Segall Bryant & Hamill Trust205,6200 00For
Nationwide150,9360 00For
Equitable71,36563,700 00Mixed
JPMorgan129,4670 00For
Invesco100,8280 00For
Manatuck Hill Partners, LLC96,0970 00For
BRIDGEWAY FUNDS INC83,5000 00For
QUANTITATIVE MASTER SERIES LLC71,6540 00For
Lincoln Financial32,72730,192 00Mixed
MASTER INVESTMENT PORTFOLIO54,0790 00For
American Century052,879 00Against
Voya42,2670 00For
Putnam031,987 00Against
ADVISORS' INNER CIRCLE FUND27,7790 00For
Goldman Sachs27,1080 00For

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

5. 3. The proposal to approve, on an advisory basis, AngioDynamics' executive compensation of its named executive officers

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 6 wordings of this item as funds reported it.

95% Approved · of votes cast

FOR 95%
FOR: 26,004,908AGAINST: 1,248,479
Details: description as filed, official tally, votes by 154 asset managers

Description as filed by funds: Say-on-Pay - An advisory vote on the approval of compensation of our named executive officers.

AngioDynamics, Inc.’s own tally for this item (“3. The proposal to approve, on an advisory basis, AngioDynamics' executive compensation of its named executive officers”): 26,004,908 for, 1,248,479 against — passed, per its Form 8-K filed November 15, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The proposal to approve, on an advisory basis, AngioDynamics' executive compensation of its named executive officers was approved based upon the following votes:”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 53 asset managers voting on “Say-on-Pay - An advisory vote on the approval of compensation of our named executive officers.” at AngioDynamics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard2,252,3660 00For
BlackRock1,914,0790 00For
Dimensional1,086,1220 00For
Fidelity984,9370 00For
TIAA941,1410 00For
Royce569,4100 00For
FIRST EAGLE FUNDS348,8960 00For
Charles Schwab330,1300 00For
Transamerica319,9000 00For
Columbia Threadneedle216,9510 00For
Segall Bryant & Hamill Trust205,6200 00For
Nationwide150,9360 00For
Equitable135,0650 00For
JPMorgan129,4670 00For
Invesco100,8280 00For
BRIDGEWAY FUNDS INC83,5000 00For
QUANTITATIVE MASTER SERIES LLC71,6540 00For
Lincoln Financial62,9190 00For
MASTER INVESTMENT PORTFOLIO54,0790 00For
American Century52,8790 00For
Voya42,2670 00For
GuideStone40,6060 00For
Putnam31,9870 00For
ADVISORS' INNER CIRCLE FUND027,779 00Against
Goldman Sachs27,1080 00For

Fund voting reports, all 53 managers: 10,390,223 for, 27,779 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 121 asset managers voting on “Say-on-Pay - An advisory vote on the approval of compensation of our named executive officers.” at AngioDynamics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
BlackRock2,116,8520 00For
SYSTEMATIC FINANCIAL MANAGEMENT LP1,370,95412,060 00For
GEODE CAPITAL MANAGEMENT, LLC967,9400 00For
Nuveen943,2960 00For
ARMISTICE CAPITAL, LLC892,3020 00For
Renaissance777,3460 00For
State Street745,9530 00For
Two Sigma717,0260 00For
STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM0450,922 00Against
SEGALL BRYANT & HAMILL, LLC432,7850 00For
Royce396,6630 00For
First Eagle Investment Management, LLC384,6140 00For
Orion Porfolio Solutions, LLC337,8240 00For
Charles Schwab330,1300 00For
Northern Trust316,8360 00For
JPMorgan315,4880 00For
ENVESTNET ASSET MANAGEMENT INC275,0480 00For
Point72273,3250 00For
DE Shaw234,4090 00For
RBC Capital Markets, LLC219,1510 00For
Dimensional209,9740 00For
KENNEDY CAPITAL MANAGEMENT LLC186,8810 00For
Mitsubishi UFJ Asset Management Co., Ltd.184,2300 00For
Citadel168,7740 00For
Allianz0166,156 00Against

Institutional-manager reports, all 121 managers: 14,906,933 for, 768,779 against, 982 not voted. Showing the 25 largest; see all in the interactive database.

6. 2. The proposal to ratify the appointment of Deloitte & Touche LLP as AngioDynamics' independent registered public…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

99.5% Approved · of votes cast

FOR 99.5%
FOR: 34,110,530AGAINST: 155,077
Details: description as filed, official tally, votes by 53 asset managers

Description as filed by funds: To ratify the appointment of Deloitte & Touche LLP as AngioDynamics, Inc. independent registered public accounting firm for the fiscal year ending May 31, 2025.

AngioDynamics, Inc.’s own tally for this item (“2. The proposal to ratify the appointment of Deloitte & Touche LLP as AngioDynamics' independent registered public accounting firm for the fiscal year ending May 31, 2025”): 34,110,530 for, 155,077 against — passed, per its Form 8-K filed November 15, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The proposal to ratify the appointment of Deloitte & Touche LLP as AngioDynamics' independent registered public accounting firm for the fiscal year ending May 31, 2025 was approved based upon the following votes:”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 53 asset managers below reported 10,417,859 for, 143 against.

FOR
FOR: 10,417,859AGAINST: 143
Largest asset managers voting on “To ratify the appointment of Deloitte & Touche LLP as AngioDynamics, Inc. independent registered public accoun” at AngioDynamics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard2,252,3660 00For
BlackRock1,914,0790 00For
Dimensional1,086,1220 00For
Fidelity984,9370 00For
TIAA941,1410 00For
Royce569,4100 00For
FIRST EAGLE FUNDS348,8960 00For
Charles Schwab330,1300 00For
Transamerica319,9000 00For
Columbia Threadneedle216,9510 00For
Segall Bryant & Hamill Trust205,6200 00For
Nationwide150,9360 00For
Equitable135,0650 00For
JPMorgan129,4670 00For
Invesco100,8280 00For
BRIDGEWAY FUNDS INC83,5000 00For
QUANTITATIVE MASTER SERIES LLC71,6540 00For
Lincoln Financial62,9190 00For
MASTER INVESTMENT PORTFOLIO54,0790 00For
American Century52,8790 00For
Voya42,2670 00For
GuideStone40,6060 00For
Putnam31,9870 00For
ADVISORS' INNER CIRCLE FUND27,7790 00For
Goldman Sachs27,1080 00For

Showing the 25 largest of 53 asset managers. See all 53 in the interactive database.

Largest AngioDynamics, Inc. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 41,004,249 shares outstanding at the time of that meeting.

Fund voting reports: top AngioDynamics, Inc. shareholders by shares voted on “Say-on-Pay - An advisory vote on the approval of compensation of our named executive officers.”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 5.49%
2BlackRock 4.67%
3Dimensional 2.65%
4Fidelity 2.40%
5TIAA 2.30%
6Royce 1.39%
7FIRST EAGLE FUNDS 0.85%
8Charles Schwab 0.81%
9Transamerica 0.78%
10Columbia Threadneedle 0.53%
Institutional-manager reports: top AngioDynamics, Inc. shareholders by shares voted on “Say-on-Pay - An advisory vote on the approval of compensation of our named executive officers.”, 2024-2025
#Asset manager % of shares outstanding
1BlackRock 5.16%
2SYSTEMATIC FINANCIAL MANAGEMENT LP 3.37%
3GEODE CAPITAL MANAGEMENT, LLC 2.36%
4Nuveen 2.30%
5ARMISTICE CAPITAL, LLC 2.18%
6Renaissance 1.90%
7State Street 1.82%
8Two Sigma 1.75%
9STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM 1.10%
10SEGALL BRYANT & HAMILL, LLC 1.06%

Reported AngioDynamics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

AngioDynamics, Inc. holdings and ownership disclosed for the 2024-2025 proxy season
Holder % outstanding Disclosure
BlackRock 8.77% 13F
SYSTEMATIC FINANCIAL MANAGEMENT LP 6.12% 13G
Vanguard Group 6.08% 13F
KEVIN KOTLER 5.91% 13G
Integrated Core Strategies (US) LLC 5.18% 13G
Armistice Capital, LLC 3.73% 13G
Nuveen 3.16% 13F
Millennium Management 3.02% 13F
Dimensional Fund Advisors 2.84% 13F
James C. Clemmer 2.73% DEF14A

Percentages above are of 41,004,249 shares outstanding, as reported by AngioDynamics, Inc. on its Form 10-Q dated August 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from AngioDynamics, Inc.’s 10-Q dated August 31, 2024. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.

At AngioDynamics, Inc.'s shareholder meeting held November 12, 2024, in the 2024-2025 proxy season, 157 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 1,148 separate fund positions. On the most widely held item on that ballot — Say-on-Pay - An advisory vote on the approval of compensation of our named executive officers. — AngioDynamics, Inc.'s filing reports the proposal as approved, with 95% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: AngioDynamics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on November 15, 2024.

AngioDynamics, Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.